Previous 10 | Next 10 |
Major Manufacturing Milestone Positions the Company for Success In the Lung Cancer Therapeutics Market, expected to grow to $26.3 Billion by 2023 Achievement Highlighted by Important Process Improvements and Significantly Improved Economies of Scale Genprex, Inc. ...
Successful Completion of Engineering Batch with Transfer from Research Institution to Commercial Contract Development and Manufacturing Organizations with Clinical Production Underway Manufacturing Technology Transfer Marks Major Company Milestone Genprex, Inc. (...
Presentation to Highlight the Company’s Recent Progress on its Upcoming Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene thera...
Acclaim-1 trial combines REQORSA™ immunogene therapy drug with AstraZeneca’s Tagrisso® Company expects to recruit approximately 10 sites across the United States Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: ...
Thomas Gallagher, Senior VP of Intellectual Property and Licensing to provide insight into IP best practices to early-stage companies Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused...
Inventor of the Company’s licensed diabetes gene therapy technology to provide leadership, strategy for diabetes program Dr. Gittes was recipient of a $2.59 million grant from the National Institutes of Health (“NIH”) National Institute of Diabetes and...
New branding will support upcoming combination clinical trials, including the Company’s trial combining REQORSA™ immunogene therapy drug with AstraZeneca’s Tagrisso ® , which received FDA Fast Track Designation earlier in 2020 Genprex, Inc. ...
Approval of new name marks important branding milestone and aligns with the program’s overall progress REQORSA immunogene therapy uses the company’s unique, proprietary ONCOPREX™ nanoparticle delivery system to deliver cancer-fighting genes FDA gra...
Promotion follows the Company’s achievement of key manufacturing milestones to support upcoming clinical trials Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing ...
The following slide deck was published by Genprex, Inc. in conjunction with this event. For further details see: Genprex (GNPX) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Genprex Issues Stockholder Letter and Provides 2024 Corporate Update PR Newswire Company Achieves Multiple Clinical Development Milestones in 2024 Patient Treatment Continues in Three Lung Cancer Clinical Trials AUSTIN, Texas , June 27, 2024 /PRNe...
Genprex to Present at the 2024 BIO International Convention PR Newswire Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: ...